Tamsulosin
- Generic Name
- Tamsulosin
- Brand Names
- Flomax, Jalyn
- Drug Type
- Small Molecule
- Chemical Formula
- C20H28N2O5S
- CAS Number
- 106133-20-4
- Unique Ingredient Identifier
- G3P28OML5I
- Background
Tamsulosin is a selective alpha-1A and alpha-1B adrenoceptor antagonist that exerts its greatest effect in the prostate and bladder, where these receptors are most common. It is indicated for the treatment of signs and symptoms of benign prostatic hypertrophy. Antagonism of these receptors leads to relaxation of smooth muscle in the prostate and detrusor muscles in the bladder, allowing for better urinary flow. Other alpha-1 adrenoceptor antagonists developed in the 1980s were less selective and more likely to act on the smooth muscle of blood vessels, resulting in hypotension.
Tamsulosin was first approved by the FDA on April 15, 1997.
- Indication
Tamsulosin is indicated for the treatment of signs and symptoms of benign prostatic hyperplasia.
Tamsulosin is also used off label for the treatment of ureteral stones, prostatitis, and female voiding dysfunction.
- Associated Conditions
- Benign Prostatic Hyperplasia (BPH), Benign Prostatic Hypertrophy, Bladder Outlet Obstruction, Ureteral Calculus
- Associated Therapies
- -
Clinical Effect and Safety of Tamsulosin 0.4mg in Patients With LUTS/BPH Refractory to Tamsulosin 0.2mg
- First Posted Date
- 2009-08-07
- Last Posted Date
- 2011-11-01
- Lead Sponsor
- Samsung Medical Center
- Target Recruit Count
- 220
- Registration Number
- NCT00954889
- Locations
- 🇰🇷
Department of Urology, Samsung Medical Center, Seoul, Korea, Republic of
Efficacy Study of Tamsulosin and Tolterodine Treatment for Chronic Prostatitis
- First Posted Date
- 2009-06-04
- Last Posted Date
- 2009-06-05
- Lead Sponsor
- Chongqing Medical University
- Target Recruit Count
- 30
- Registration Number
- NCT00913315
- Locations
- 🇨🇳
Department of Urology, the First Affiliated Hospital of Chongqing Medical University, Chongqing, Chongqing, China
Multinational Study to Evaluate Tadalafil in Asian Men With Signs and Symptoms of Benign Prostatic Hyperplasia
- Conditions
- Benign Prostatic Hyperplasia
- Interventions
- First Posted Date
- 2009-03-13
- Last Posted Date
- 2011-06-28
- Lead Sponsor
- Eli Lilly and Company
- Target Recruit Count
- 612
- Registration Number
- NCT00861757
- Locations
- 🇨🇳
For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Tao-Yuan, Taiwan
Medical Expulsive Therapy of Single Distal Ureteral Stones
- First Posted Date
- 2009-01-29
- Last Posted Date
- 2010-05-25
- Lead Sponsor
- University of Zurich
- Target Recruit Count
- 100
- Registration Number
- NCT00831701
- Locations
- 🇨🇭
Department of Urology, University Hospital Zürich, Switzerland, Zurich, Switzerland
Study to Evaluate the Efficacy and Safety of Tamsulosin in Children With Neurogenic Bladder
- Conditions
- Bladder, Neurogenic
- Interventions
- Drug: PlaceboDrug: tamsulosin hydrochloride
- First Posted Date
- 2008-11-24
- Last Posted Date
- 2015-10-29
- Lead Sponsor
- Boehringer Ingelheim
- Target Recruit Count
- 231
- Registration Number
- NCT00796614
Solifenacin as Add-on Therapy for Overactive Bladder Symptoms in Men Treated for Benign Prostatic Hyperplasia
- Conditions
- Benign Prostatic HyperplasiaBenign Prostatic HypertrophyOveractive Bladder
- Interventions
- First Posted Date
- 2008-10-13
- Last Posted Date
- 2013-02-15
- Lead Sponsor
- Astellas Pharma Inc
- Target Recruit Count
- 638
- Registration Number
- NCT00771394
Dutasteride and Flex Dose of Tamsulosin on as Needed Basis, to Treat Benign Prostatic Hyperplasia
- First Posted Date
- 2008-06-19
- Last Posted Date
- 2018-11-02
- Lead Sponsor
- Siami, Paul F., M.D.
- Target Recruit Count
- 63
- Registration Number
- NCT00701779
- Locations
- 🇺🇸
Research Institute of Deaconess Clinic, Evansville, Indiana, United States
Prevention of Acute Voiding Difficulty After Radical Proctectomy
- First Posted Date
- 2008-02-05
- Last Posted Date
- 2011-07-20
- Lead Sponsor
- Seoul National University Hospital
- Target Recruit Count
- 100
- Registration Number
- NCT00606983
- Locations
- 🇰🇷
Department of Surgery, Seoul National University Bundang Hospital, Seongnam, Korea, Republic of
The Efficacy of Tamsulosin in the Treatment of Ureteral Stones in Emergency Department Patients
- Conditions
- NephrolithiasisUreteral Calculi
- Interventions
- Drug: tamsulosinDrug: Standard therapy with ibuprofen and oxycodone.
- First Posted Date
- 2008-01-25
- Last Posted Date
- 2008-01-25
- Lead Sponsor
- MaineHealth
- Target Recruit Count
- 81
- Registration Number
- NCT00600405
- Locations
- 🇺🇸
Maine Medical Center, Portland, Maine, United States
Pilot Study Investigating Safety and Efficacy of Tadalafil as Treatment for Benign Prostatic Hyperplasia (BPH) in Asian Men
- Conditions
- Benign Prostatic Hyperplasia
- Interventions
- First Posted Date
- 2007-10-05
- Last Posted Date
- 2010-11-25
- Lead Sponsor
- Eli Lilly and Company
- Target Recruit Count
- 151
- Registration Number
- NCT00540124
- Locations
- 🇰🇷
For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Seoul, Korea, Republic of
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.